ATE137119T1 - Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen - Google Patents

Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen

Info

Publication number
ATE137119T1
ATE137119T1 AT88908490T AT88908490T ATE137119T1 AT E137119 T1 ATE137119 T1 AT E137119T1 AT 88908490 T AT88908490 T AT 88908490T AT 88908490 T AT88908490 T AT 88908490T AT E137119 T1 ATE137119 T1 AT E137119T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
human beings
treating malignant
conjugated
treat
Prior art date
Application number
AT88908490T
Other languages
English (en)
Inventor
Thomas A Waldmann
Original Assignee
Us Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Commerce filed Critical Us Commerce
Application granted granted Critical
Publication of ATE137119T1 publication Critical patent/ATE137119T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT88908490T 1987-08-17 1988-08-11 Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen ATE137119T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8570787A 1987-08-17 1987-08-17

Publications (1)

Publication Number Publication Date
ATE137119T1 true ATE137119T1 (de) 1996-05-15

Family

ID=22193428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88908490T ATE137119T1 (de) 1987-08-17 1988-08-11 Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen

Country Status (7)

Country Link
US (1) US20050207975A1 (de)
EP (1) EP0380542B1 (de)
JP (1) JP2581788B2 (de)
AT (1) ATE137119T1 (de)
CA (1) CA1325591C (de)
DE (1) DE3855236D1 (de)
WO (1) WO1989001340A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
WO1989006968A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
US5276348A (en) * 1992-06-09 1994-01-04 Advanced Photonix, Inc. Dot matrix pattern on photosensitive semi-conductor surface
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
FI95441C (fi) * 1994-05-31 1996-02-12 Leiras Oy Inhalointilaitteen lääkeainekammio
KR100465820B1 (ko) * 2002-04-16 2005-01-13 심대근 문짝용 플라스틱 판넬 및 그 제조 방법
PL217296B1 (pl) 2002-11-15 2014-07-31 Genmab As Wyizolowane ludzkie przeciwciało monoklonalne, wytwarzająca je hybrydoma, kodujący to przeciwciało wektor ekspresyjny i zawierająca je kompozycja farmaceutyczna, immunokoniugat, bispecyficzna lub multispecyficzna cząsteczka obejmująca kwasy nukleinowe kodujące ciężki i lekki łańcuch transfektoma, ich zastosowania, zwłaszcza w medycynie, obejmująca te kwasy ex vivo eukariotyczna lub prokariotyczna komórka gospodarza oraz nie będące człowiekiem zwierzę transgeniczne lub roślina, sposób in vitro hamowania wzrostu i/lub proliferacji komórek wyrażających CD25 lub eliminowania komórek wyrażających CD25, sposób wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25, zestaw diagnostyczny do wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US903723A (en) * 1907-12-23 1908-11-10 Nelson Hughes Buckle.
SU438419A1 (ru) * 1968-05-31 1974-08-05 Н. Б. Михеев, М. А. Грачева , А. И. Журба Институт биофизики Способ получения коллоидного растворас иттрием-90
DE2011612C3 (de) * 1970-03-11 1974-03-21 Institut Medizinskoi Radiologii Amn Ssr, Ussr, Obninsk (Sowjetunion) Radionuklide enthaltende, resorbierbare Fäden und Filme
US4709015A (en) * 1979-12-04 1987-11-24 Ortho Pharmaceutical Corporation Monoclonal antibody to human suppressor T cells
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4819150A (en) * 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
FR2616330B1 (fr) * 1987-06-12 1990-12-21 Immunotech Sa Agent actif et medicament en contenant destines a prevenir ou a combattre le rejet de greffe d'organe chez l'homme
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins

Also Published As

Publication number Publication date
US20050207975A1 (en) 2005-09-22
WO1989001340A1 (en) 1989-02-23
JP2581788B2 (ja) 1997-02-12
EP0380542A4 (en) 1990-12-05
DE3855236D1 (de) 1996-05-30
EP0380542B1 (de) 1996-04-24
CA1325591C (en) 1993-12-28
JPH03500645A (ja) 1991-02-14
EP0380542A1 (de) 1990-08-08

Similar Documents

Publication Publication Date Title
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE3485688D1 (de) Verfahren und vorrichtung zur behandlung von krankheiten.
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
GB2122496A (en) Method and apparatus for the treatment of autoimmune and allergic diseases
MY111961A (en) Therapeutic method
DE3588082D1 (de) Verfahren und zusammensetzungen zur verwendung in der diagnose und behandlung autoimmuner krankheiten
HUT36859A (en) Tumer-specific monoclinal antibodies
EP0069232A3 (en) Purified antineoplaston fractions and methods of treating neoplastic disease
ATE137119T1 (de) Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen
ATE1443T1 (de) Mittel zur behandlung allergischer reaktionen.
JPS57131721A (en) Drug treatment for body disease
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
NL187299B (nl) Gevormde farmaceutische doseringseenheid voor het behandelen van hart- en vaatziekten.
DE3789958D1 (de) Verfahren und Apparat zur Bestrahlungsbehandlung, angepasst an das Frequenzspektrum des menschlichen Körpers.
EP0642333A4 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion.
EP0444156A4 (en) Method for treating vascular diseases
IE811612L (en) Thiazoles
DE68902212D1 (de) Immunotoxine zur behandlung bzw. prophylaxe von autoimmunkrankheiten.
GB2126080A (en) Agent for treating allergic disease immunity complex disease and tumor
ATE167398T1 (de) Behandlungsverfahren für therapiewiderstehende schizophrenie mit amperozide
BE888543A (fr) Procedes et machines pour le traitement de pierres precieuses,
DE3280419D1 (de) Medizinisches praeparat zur behandlung von hautleiden.
SE8306384L (sv) Farmaceutisk komposition
PT75226B (en) Method for diagnosing and for the therapeutic treatment of tu- mors diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties